Ocugen Acquires Histogenics Corporation

Ocugen Acquires Histogenics Corporation

Ocugen, Inc., a privately held clinical-stage biopharmaceutical company, has acquired Histogenics Corporation (NASDAQ: HSGX). Although no financial terms were disclosed, the merged company will be publicly-traded, operating under the Ocugen name. Ocugen discovers, develops and commercializes a pipeline of innovative therapies that address rare and underserved eye diseases. Histogenics develops a restorative cell therapy technology platform. It has collaborated with Brigham and Women’s Hospital, Cornell University and other leading institutions to advance molecular biology and proprietary materials sciences. Perhaps a big factor driving Ocugen’s purchase is Histogenic’s pipeline... Read More »

First Half of 2016 Shows Strength in M&A

Ever since the rally in health care mergers and acquisitions began in 2014, we’ve been waiting for the inevitable slam-on-the-brakes quarter. That rally was sparked by the advent of newly insured families and individuals entering the healthcare market, beginning on January 1, 2014. Thanks to the Affordable Care Act, passed in 2010, health care M&A topped 1,000 transactions that year and has never looked back. Isn’t it about time for the party to end? Not according to our data for the first six months of 2016, compared with the same period in 2014 and 2015. (But if you read our monthly M&A roundup on page 18, you may have second thoughts.) In the first half of 2016, deal volume... Read More »